Chronic effects of cannabis on sensory gating

International Journal of Psychophysiology

Volumn 89, Issue 3, 2013, Pages 381-389

  Broyd, Samantha J ^a   Greenwood, Lisa marie ^a   Croft, Rodney J ^a   Dalecki, Anna ^a   Todd, Juanita ^b,c   Michie, Patricia T ^b,c   Johnstone, Stuart J ^a   Solowij, Nadia ^a,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Cannabis; Event related potentials; P50; Schizophrenia; Sensory gating

Indexed keywords

CANNABIS;

ADULT; ALCOHOL CONSUMPTION; AMPLITUDE MODULATION; ARTICLE; CANNABACEAE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISTRESS SYNDROME; EDUCATION; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; LEARNING; LONG TERM EXPOSURE; MALE; METABOLITE; PARANOIA; PSYCHOSIS; SENSORY GATING; SMOKING; WAVEFORM;

CANNABIS; EVENT-RELATED POTENTIALS; P50; SCHIZOPHRENIA; SENSORY GATING;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SENSORY GATING; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84885385607     PISSN: 01678760     EISSN: 18727697     Source Type: Journal    
DOI: 10.1016/j.ijpsycho.2013.04.015     Document Type: Article

References (83)

1. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 1998, 24:189-202.
2. Andrews G., Slade T. Interpreting scores on the Kessler Psychological Distress Scale (k10). Australian and New Zealand Journal of Public Health 2001, 25:494-497.
3. Barkus E., Stirling J., Hopkins R., Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 2006, 39:175-178.
4. Bhattacharyya S., Crippa J.A., Martin-Santos R., Winton-Brown T., Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Current Pharmaceutical Design 2009, 15:2603-2614.
5. Bossong M.G., Niesink R.J.M. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology 2010, 92:370-385.
6. Boutros N.N., Belger A. Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating. Biological Psychiatry 1999, 45:917-922.
7. Boutros N.N., Kwan S.W. Test-retest reliability of the rat N40 auditory evoked response: preliminary data. Psychiatry Research 1998, 81:269-276.
8. Boutros N.N., Overall J., Zouridakis G. Test-retest reliability of the P50 midlatency auditory evoked-response. Psychiatry Research 1991, 39:181-192.
9. Boutros N.N., Bonnet K.A., Millana R., Liu J. A parametric study of the N40 auditory evoked response in rats. Biological Psychiatry 1997, 42:1051-1059.
10. Boutros N.N., Gjini K., Eickhoff S.B., Urbach H., Pflieger M.E. Mapping repetition suppression of the P50 evoked response to the human cerebral cortex. Clinical Neurophysiology 2013, 124:675-685.
11. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Archives of General Psychiatry 1990, 47:181-188.
12. Braff D.L., Light G.A. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues in Clinical Neuroscience 2005, 7:125-135.
13. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 2004, 70:315-329.
14. Brenner C.A., Kieffaber P.D., Clementz B.A., Johannesen J.K., Shekhar A., O'Donnell B.F., Hetrick W.P. Event-related potential abnormalities in schizophrenia: a failure to "gate in" salient information?. Schizophrenia Research 2009, 113:332-338.
15. Budney A.J., Hughes J.R., Moore B.A., Vandrey R.G. A review of the validity and significance of the cannabis withdrawal syndrome. The American Journal of Psychiatry 2004, 161:1967-1977.
16. Chang W.P., Arfken C.L., Sangal M.P., Boutros N.N. Probing the relative contribution of the first and second responses to sensory gating indices: a meta-analysis. Psychophysiology 2011, 48:980-992.
17. Clementz B.A., Blumenfeld L.D. Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia. Experimental Brain Research 2001, 139:377-390.
18. Clementz B.A., Geyer M.A., Braff D.L. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biological Psychiatry 1997, 41:1035-1044.
19. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophrenia Research 1998, 30:71-80.
20. Clementz B.A., Geyer M.A., Braff D.L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. The American Journal of Psychiatry 1998, 155:1691-1694.
21. Crawford H.J., McClain-Furmanski D., Castagnoli N., Castagnoli K. Enhancement of auditory sensory gating and stimulus-bound gamma band (40Hz) oscillations in heavy tobacco smokers. Neuroscience Letters 2002, 317:151-155.
22. Croft R.J., Barry R.J. EOG correction: which regression should we use?. Psychophysiology 2000, 37:123-125.
23. Croft R.J., Lee A., Bertolot J., Gruzelier J.H. Associations of P50 suppression and desensitization with perceptual and cognitive features of "unreality" in schizotypy. Biological Psychiatry 2001, 50:441-446.
24. Croft R.J., Dimoska A., Gonsalvez C.J., Clarke A.R. Suppression of P50 evoked potential component, schizotypal beliefs and smoking. Psychiatry Research 2004, 128:53-62.
25. Dalecki A., Croft R.J., Johnstone S.J. An evaluation of P50 paired-click methodologies. Psychophysiology 2011, 48:1692-1700.
26. de Wilde O.M., Bour L.J., Dingemans P.M., Koelman J.H., Linszen D.H. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophrenia Research 2007, 97:137-151.
27. Dissanayake D.W., Zachariou M., Marsden C.A., Mason R. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2. Neuropharmacology 2008, 55:1397-1404.
28. Dissanayake D.W., Mason R., Marsden C.A. Sensory gating, cannabinoids and schizophrenia. Neuropharmacology 2013, 67C:66-77.
29. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience 2009, 259:413-431.
30. Edwards C.R., Skosnik P.D., Steinmetz A.B., O'Donnell B.F., Hetrick W.P. Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations. Behavioral Neuroscience 2009, 123:894-904.
31. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a deficit in inhibitory pathways in schizophrenia - a comparison of medicated and drug-free participants. Biological Psychiatry 1983, 18:537-551.
32. Freedman R., Adler L.E., Myles-Worsley M., Nagamoto H.T., Miller C., Kisley M., McRae K., Cawthra E., Waldo M. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Archives of General Psychiatry 1996, 53:1114-1121.
33. Gallinat J., Rentzsch J., Roser P. Neurophysiological effects of cannabinoids: implications for psychosis research. Current Pharmaceutical Design 2012, 18:4938-4949.
34. Gjini K., Arfken C., Boutros N.N. Relationships between sensory "gating out" and sensory "gating in" of auditory evoked potentials in schizophrenia: a pilot study. Schizophrenia Research 2010, 121:139-145.
35. Gjini K., Burroughs S., Boutros N.N. Relevance of attention in auditory sensory gating paradigms in schizophrenia: a pilot study. Journal of Psychophysiology 2011, 25:60-66.
36. Gossop M., Marsden J., Stewart D. Dual dependence: assessment of dependence upon alcohol and illicit drugs, and the relationship of alcohol dependence among drug misusers to patterns of drinking, illicit drug use and health problems. Addiction 2002, 97:169-178.
37. Greenwood L-m., Broyd S.J., Croft R.J., Todd J., Michie P.T., Johnstone S.J., Murray R., Solowij N. Chronic effects of cannabis use on the auditory mismatch negativity. Biological Psychiatry 2013, (in press).
38. Grunwald T., Boutros N.N., Pezer N., von Oertzen J., Fernandez G., Schaller C., Elger C.E. Neuronal substrates of sensory gating within the human brain. Biological Psychiatry 2003, 53:511-519.
39. Hajos M., Rogers B.N. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Current Pharmaceutical Design 2010, 16:538-554.
40. Hajos M., Hoffmann W.E., Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biological Psychiatry 2008, 63:1075-1083.
41. Hampson R.E., Miller F., Palchik G., Deadwyler S.A. Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology 2011, 60:944-952.
42. Heifets B.D., Castillo P.E. Endocannabinoid signalling and long-term synaptic plasticity. Annual Review of Physiology 2009, 71:283-306.
43. Hoffman A.F., Oz M., Yang R., Lichtman A.H., Lupica C.R. Opposing actions of δ9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learning and Memory 2007, 14:63-74.
44. Hu L., Boutros N.N., Jansen B.H. Sensory gating-out and gating-in in normal and schizophrenic participants. Clinical EEG and Neuroscience 2012, 43:23-31.
45. Iversen L. How cannabis works in the brain. Marijuana and Madness: Psychiatry and Neurobiology 2004, 19-40. Cambridge University Press, West Nyack, NY, USA. D. Castle, R. Murray (Eds.).
46. Jansen B.H., Hegde A., Boutros N.N. Contribution of different EEG frequencies to auditory evoked potential abnormalities in schizophrenia. Clinical Neurophysiology 2004, 115:523-533.
47. Jerger K., Biggins C., Fein G. P50 suppression is not affected by attentional manipulations. Biological Psychiatry 1992, 31:365-377.
48. Kho K.H., Verkes R.J., Eling P., Zwarts M.J., Ellenbroek B., van Luijtelaar G. P50 gating is not affected by selective attention. Journal of Psychophysiology 2003, 17:23-29.
49. Knott V., Millar A., Fisher D. Sensory gating and source analysis of the auditory P50 in low and high suppressors. NeuroImage 2009, 44:992-1000.
50. Korzyukov O., Pflieger M.E., Wagner M., Bowyer S.M., Rosburg T., Sundaresan K., Elger C.E., Boutros N.N. Generators of the intracranial P50 response in auditory sensory gating. NeuroImage 2007, 35:814-826.
51. Lopez-Moreno J.A., Gonzalez-Cuevas G., Moreno G., Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addiction Biology 2008, 13:160-187.
52. Martin-Santos R., Fagundo A.B., Crippa J.A., Atakan Z., Bhattacharyya S., Allen P., Fusar-Poli P., Borgwardt S., Seal M., Busatto G.F., McGuire P. Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine 2010, 40:383-398.
53. Mathur B.N., Lovinger D.M. Endocannabinoid-dopamine interactions in striatal synaptic plasticity. Frontiers in Pharmacology 2012, 3:66.
54. Murray R.M., Morrison P.D., Henquet C., Di Forti M. Cannabis, the mind and society: the hash realities. Nature Reviews Neuroscience 2007, 8:885-895.
55. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychololgia 1971, 9:97-113.
56. Patrick G., Struve F.A. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clinical Electroencephalography 2000, 31:88-93.
57. Patrick G., Struve F. Reduced P50 sensory gating in heavy marihuana users. International Journal of Psychophysiology 2002, 45:33-34.
58. Patrick G., Straumanis J.J., Struve F.A., Fitz-Gerald M.J., Leavitt J., Manno J.E. Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biological Psychiatry 1999, 45:1307-1312.
59. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., Potkin S., Bunney W.E. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Research 2008, 158:226-247.
60. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and delta(9)-tetrahydrocannabivarin. British Journal of Pharmacology 2008, 153:199-215.
61. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry 2001, 58:909-915.
62. Potter D., Summerfelt A., Gold J., Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophrenia Bulletin 2006, 32:692-700.
63. Puighermanal E., Busquets-Garcia A., Maldonado R., Ozaita A. Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2012, 367:3254-3263.
64. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin 1991, 17:555-564.
65. Rentzsch J., Penzhorn A., Kernbichler K., Plockl D., de Castro A.G.C., Gallinat J., Jockers-Scherubl M.C. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Experimental Neurology 2007, 205:241-249.
66. Rentzsch J., Buntebart E., Stalelmeier A., Gallinat J., Jockers-Scheruebl M.C. Differential effects of chronic cannabis use on preattentional cognitive functioning in abstinent schizophrenic patients and healthy subjects. Schizophrenia Research 2011, 130:222-227.
67. Roser P., Della B., Norra C., Uhl I., Bruene M., Juckel G. Auditory mismatch negativity deficits in long-term heavy cannabis users. European Archives of Psychiatry and Clinical Neuroscience 2010, 260:491-498.
68. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993, 88:791-804.
69. Semple D.M., McIntosh A.M., Lawrie S.M. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 2005, 19:187-194.
70. Smith D.A., Boutros N.N., Schwarzkopf S.B. Reliability of P50 auditory event-related potential indexes of sensory gating. Psychophysiology 1994, 31:495-502.
71. Smith A.K., Edgar J.C., Huang M., Lu B.Y., Thoma R.J., Hanlon F.M., McHaffie G., Jones A.P., Paz R.D., Miller G.A., Canive J.M. Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia. The American Journal of Psychiatry 2010, 167:1264-1275.
72. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. Journal of Psychiatry & Neuroscience 2007, 32:30-52.
73. Solowij N., Pesa N. Cognitive abnormalities and cannabis use. Revista Brasileira De Psiquiatria 2010, 32:S31-S40.
74. Solowij N., Michie P.T., Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biological Psychiatry 1995, 37:731-739.
75. Solowij N., Yücel M., Respondek C., Whittle S., Lindsay E., Pantelis C., Lubman D.I. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychological Medicine 2011, 41:2349-2359.
76. Stefanis N., Hanssen M., Smirnis N., Avramopoulos D., Evdokimidis I., Stefanis C., Verdoux H., Os V.J. Evidence that three dimensions of psychosis have a distribution in the general population. Psychological Medicine 2002, 32:347-358.
77. Thoma R.J., Hanlon F.M., Moses S.N., Ricker D., Huang M., Edgar C., Irwin J., Torres F., Weisend M.P., Adler L.E., Miller G.A., Canive J.M. M50 sensory gating predicts negative symptoms in schizophrenia. Schizophrenia Research 2005, 73:311-318.
78. Todd J., Michie P.T., Schall U., Karayanidis F., Yabe H., Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biological Psychiatry 2008, 63:58-64.
79. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI) 1999, Harcourt Assessment, San Antonio TX.
80. Weisser R., Weisbrod M., Roehrig M., Rupp A., Schroeder J., Scherg M. Is frontal lobe involved in the generation of auditory evoked P50?. NeuroReport 2001, 12:3303-3307.
81. White P.M., Yee C.M. Effects of attentional and stressor manipulations on the P50 gating response. Psychophysiology 1997, 34:703-711.
82. Yücel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., Lubman D.I. Long-term heavy cannabis use related brain abnormalities. Early Intervention in Psychiatry 2008, 2:A31-A.
83. Yücel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., Lubman D.I. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry 2008, 65:694-701.